SEOUL VIOSYS CO., LTD.: debt-to-equity, ROE and more
KOSDAQ, Legal name SEOUL VIOSYS CO., LTD.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 322.5%
- Equity ratio
- 23.7%
- ROE
- -8.0%
- Op. margin
- 0.0%
- Rev. growth
- 9.2%
- Interest coverage
- n/a
Condition flags
- Operating profit for 2 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 201.4% | 33.2% | 8.1% | 4.6% | n/a |
| FY2022 consolidated | 351.3% | 22.2% | -55.9% | -14.2% | -10.2% |
| FY2023 consolidated | 689.1% | 12.7% | -109.4% | -14.5% | 14.9% |
| FY2024 consolidated | 494.2% | 16.8% | 13.5% | 0.5% | 38.7% |
| FY2025 consolidated | 322.5% | 23.7% | -8.0% | 0.0% | 9.2% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩488.7B | ₩438.8B | ₩504.0B | ₩699.2B | ₩763.8B |
| Operating profit | ₩22.3B | -₩62.1B | -₩72.9B | ₩3.5B | ₩225.8M |
| Pre-tax income | ₩19.5B | -₩80.8B | -₩100.6B | ₩18.9B | -₩14.6B |
| Net income | ₩20.9B | -₩93.7B | -₩101.7B | ₩18.1B | -₩13.6B |
| Total assets | ₩775.6B | ₩756.0B | ₩733.4B | ₩795.8B | ₩717.8B |
| Total liabilities | ₩518.3B | ₩588.5B | ₩640.5B | ₩661.9B | ₩547.9B |
| Total equity | ₩257.4B | ₩167.5B | ₩92.9B | ₩133.9B | ₩169.9B |
| Paid-in capital | ₩19.1B | ₩19.1B | ₩22.9B | ₩22.9B | ₩22.9B |
| Debt/equity (source value) | 201.4% | 351.3% | 689.1% | 494.2% | 322.5% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2002-01-25
- Listed
- 20/03/06
- Employees
- 194
- Auditor
- 정진세림회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1350110122156
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 서울바이오시스Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.